Compare Gilead Sciences, Inc. (GILD) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs PepsiCo, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.49 (market cap $168.35B), while PepsiCo, Inc. trades at $138.19 (market cap $188.91B). The key difference: Gilead Sciences, Inc. and PepsiCo, Inc. are close in size by market cap, and PepsiCo, Inc. pays the higher dividend (4.28%). Which is the better fit depends on your goals.
| GILD | PEP | |
|---|---|---|
Market Cap | $168.35B | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $170.44 |
52-Week Low | $110.56 | $134.95 |
Enterprise Value | $191.42B | $231.41B |
Dividend Yield | 2.42% | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PepsiCo (PEP) trades at $137.69, down 0.95% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 10.78% net margin and 51.59% ROE, though Q3 2026 earnings are pending. Recent news highlights price adjustments on snack products and sponsorship changes, while analysts maintain a consensus Buy rating with $158.79 price target.
PEP offers steady dividend income and operational stability, but faces near-term pressure from consumer resistance to price hikes and competitive threats. The stock trades below consensus target with mixed technical indicators, presenting potential value for long-term investors willing to navigate current volatility and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
